Tinactin


Also found in: Dictionary, Encyclopedia.

tolnaftate

(tol-naff-tate) ,

Lamisil AF

(trade name),

Pitrex

(trade name),

Podactin

(trade name),

Tinactin

(trade name),

Ting

(trade name),

Tolnaftate-D

(trade name)

Classification

Therapeutic: antifungals
Pregnancy Category: C

Indications

Treatment of a variety of cutaneous fungal infections, including tinea pedis (athlete’s foot), tinea cruris (jock itch), and tinea corporis (ringworm).

Action

Distorts the hyphae and stunts mycelial growth in fungi.

Therapeutic effects

Decrease in symptoms of fungal infection.

Pharmacokinetics

Absorption: Absorption through intact skin is minimal.
Distribution: Distribution after topical administration is primarily local.
Metabolism and Excretion: Systemic metabolism and excretion not known following local application.
Half-life: Not applicable.

Time/action profile

ROUTEONSETPEAKDURATION
Topical24–72 hrunknownunknown

Contraindications/Precautions

Contraindicated in: Hypersensitivity to active ingredients, additives, preservatives, or bases; Some products contain alcohol and should be avoided in patients with known intolerance.
Use Cautiously in: Nail and scalp infections (may require additional systemic therapy); Obstetric / Lactation: Safety not established.

Adverse Reactions/Side Effects

Local

  • burning
  • itching
  • local hypersensitivity reactions
  • redness
  • stinging

Interactions

Drug-Drug interaction

Not known.

Route/Dosage

Topical (Adults and Children ≥2 yr) Apply twice daily for up to 2 wk for tinea cruris and for up to 4 wk for tinea pedis or tinea corporis.

Availability (generic available)

Cream: 1%OTC
Powder: 1%OTC
Solution: 1%OTC
Spray liquid: 1%OTC
Spray powder: 1%OTC

Nursing implications

Nursing assessment

  • Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Indications)
Risk for infection (Indications)

Implementation

  • Consult health care professional for proper cleansing technique before applying medication.
  • Topical: Apply small amount to cover affected area completely. Avoid the use of occlusive wrappings or dressings unless directed by health care professional.

Patient/Family Teaching

  • Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes.
  • Caution patient that some products may stain fabric, skin, or hair. Check label information. Fabrics stained from cream can usually be cleaned by handwashing with soap and warm water.
  • Patients with athlete’s foot should be taught to wear well-fitting, ventilated shoes, to wash affected areas thoroughly, and to change shoes and socks at least once a day.
  • Advise patient to report increased skin irritation or lack of response to therapy to health care professional.

Evaluation/Desired Outcomes

  • Decrease in skin irritation and resolution of infection. Early relief of symptoms may be seen in 2–3 days. For tinea cruris and tinea corporis, 2 wk are needed, and for tinea pedis, therapeutic response may take 4 wk. Recurrent fungal infections may be a sign of systemic illness.
References in periodicals archive ?
2 brand with $31.3 million in sales, edged up only 0.2% from the year before; Tinactin, the No.
(+1.1%) Market Dollar sales Leading brands ** Manufacturer share (000) Lamisil AT Novartis 14.5% $24,166 Lotrimin AF Schering-Plough 10.0% 16,578 Tinactin Schering-Plough 7.9% 13,064 Dr.
year ago Total mass market ([dagger]) +1.7% Drug stores +5.2% Supermarkets -1.4% Best-sellers in drug stores Dollar Brand Manufacturer market share Lamisil AT Novartis 13.9% Lotrimin AF Schering-Plough 10.4% Tinactin Schering-Plough 8.5% Lotrimin Ultra Schering-Plough 4.2% Kerasal Taro Pharmaceuticals 4.0% Dr.
Major Products: Foot care--Lotrimin AF and Tinactin anti-fungals; Sun care--Coppertone and Bain de Soleil.
Scholl's devices Schering-Plough 13.1% $37,990 Lamisil AT Novartis 8.0% 23,296 Lotrimin AF Schering-Plough 5.9% 17,042 Tinactin Schering-Plough 4.8% 13,786 Dr.
markets Lotrimin AF, Lotrimin Ultra, Tinactin and Dr.
Besides the Lotramin line, Schering-Plough markets the best-selling brands Tinactin and Dr.
Also, Fougera's Consumer Products division has launched over-the-counter TipTapToe tolnaftate solution (a version of Tinactin) in a new, more convenient delivery vehicle.
Lotrimin AF and Tinactin antifungal products maintained their No.
Schering-Plough has responded with its Tinactin athlete's foot medications, which seeks to prevent athlete's foot, instead of alleviating its discomfort.
Its Lotrimin AF and Tinactin lines ranked first and third among the top-selling brands, with sales of $50 million and $44.4 million, while Dr.
Store brands rank fourth behind Schering-Plough's Lotrimin, Novartis Consumer Health Inc.'s Lamisil AT and Schering-Plough's Tinactin. But while two of the top three brands saw sales declines and Lamisil AT gained less than 3%, private label volume climbed 11.9%.